Associations between the ALSFRS‐R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS‐R scores in clinical studies MCI186 ‐16, MCI186 ‐17, and MCI186 ‐19

Autor: Fumihiro Takahashi, Osamu Kano, Yoshito Nagano, Takatomo Yoneoka, Sally Nelson, Yoshiteru Ushirogawa

Publikováno v: Muscle & Nerve. 66:593-602

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::244227b94adc42f30feeca0b03ec4748
https://doi.org/10.1002/mus.27700

Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19

Autor: Fumihiro, Takahashi, Osamu, Kano, Yoshito, Nagano, Takatomo, Yoneoka, Sally, Nelson, Yoshiteru, Ushirogawa

Publikováno v: MusclenerveREFERENCES. 66(5)

Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19). Those trials enrolled patients with Japanese ALS severity grades 1 and 2 (less severe ALS), but many patients progressed to grades 3 and 4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::18ff6556a6207c4658b0ef304b1733a3
https://pubmed.ncbi.nlm.nih.gov/36054038

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Autor: Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino, Hidenao Sasaki, Ichiro Yabe, Shizuki Doi, Hitoshi Warita, Takashi Imai, Hiroaki Ito, Mitsumasa Fukuchi, Etsuko Osumi, Manabu Wada, Imaharu Nakano, Mitsuya Morita, Katsuhisa Ogata, Yuichi Maruki, Kimiko Ito, Osamu Kano, Mineo Yamazaki, Yuji Takahashi, Hiroyuki Ishiura, Mieko Ogino, Ryoko Koike, Chiho Ishida, Tsuyoshi Uchiyama, Kouichi Mizoguchi, Tomokazu Obi, Hirohisa Watanabe, Naoki Atsuta, Ikuko Aiba, Akira Taniguchi, Hideyuki Sawada, Takanori Hazama, Harutoshi Fujimura, Hirofumi Kusaka, Takenobu Kunieda, Hitoshi Kikuchi, Hidenori Matsuo, Hidetsugu Ueyama, Kazutoshi Uekawa, Masaki Ueda, Aiko Murakami, Rie Sumii, Takuya Kudou, Kazunori Morimoto, Takatomo Yoneoka, Manabu Hirai, Kouichi Sasaki, Hidetomo Terai, Tomoko Natori, Hiroshi Matsui, Kuniko Kotani, Kaori Yoshida, Tomohisa Iwasaki

Publikováno v: The Lancet. Neurology. 16(7)

Summary Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c0c60fc2d53d0c25417d88e071eb4c
https://pubmed.ncbi.nlm.nih.gov/32822626

Changes in nerve growth factor content of the submaxillary gland in the genetically dystrophic (mdx) mouse

Autor: Toshiaki Ito, Takatomo Yoneoka, Ichizo Shinoda, Kyozo Hayashi, Shoei Furukawa, Yoshiko Furukawa, Masao Hirota

Publikováno v: Journal of the neurological sciences. 121(2)

We evaluated the nerve growth factor (NGF) contents in the submaxillary gland of the mdx mouse, a model for Duchenne muscular dystrophy (DMD), and found that the NGF and NGF mRNA contents in this organ, where extraordinarily high amounts of NGF are s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520d895a1fcef552b428d0b398474918
https://pubmed.ncbi.nlm.nih.gov/8158212